Anticorps Recombinant de lapin anti-IGFBP6

IGFBP6 Recombinant Antibody for WB, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

241724H5

N° de cat : 84364-5-PBS

Synonymes

IGF-binding protein 6, IGF binding protein 6, IBP-6, IBP6, IBP 6

---

Galerie de données de validation

• 

  WB analysis of human testis using 84364-5-RR (same clone as 84364-5-PBS)

  human testis tissue were subjected to SDS PAGE followed by western blot with 84364-5-RR (IGFBP6 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 84364-5-PBS in a different storage buffer formulation.

• 

  Affinity and Kinetic Characterization of 84364-5-RR

  Biolayer interferometry (BLl) kinetic assays of 84364-5-RR against Human IGFBP6 were performed. The affinity constant is 0.259 nM.

---

Informations sur le produit

84364-5-PBS cible IGFBP6 dans les applications de WB, Indirect ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Recombinant
• Type: Anticorps
• Immunogène: Protéine recombinante
• Nom complet: insulin-like growth factor binding protein 6
• Masse moléculaire calculée: 25 kDa
• Poids moléculaire observé: 34 kDa
• Numéro d’acquisition GenBank: BC011708
• Symbole du gène: IGFBP6
• Identification du gène (NCBI): 3489
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Protein A purfication
• Tampon de stockage: PBS only
• Conditions de stockage: Store at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

Insulin-like growth factor (IGF) binding protein (IGFBP6), a 240 amino acid protein, contains an IGFBP N-terminal domain and a thyroglobulin type-1 domain. It modulates the activity of IGF and shows independent effects of IGF, such as growth inhibition and apoptosis. It can decrease the proliferation and survival of cancer cells such as lung cancer cells and naso-pharyngeal cancer cells. IGFBP-6 is distinctive for its 50-fold higher binding affinity for IGF-II over IGF-I and this specificity makes it an attractive potential therapeutic candidate for IGF-II-dependent pediatric malignancies such as rhabdomyosarcoma (RMS). In addition, it was found that IGFBP6 can promote the migration of RMS cells in an IGF-independent manner, and MAPK pathways were involved in this process. Further study reported that IGFBP6 is one of most highly expressed proteins in varicose vein tissues and is involved in the proliferation of vascular smooth muscle cells (VSMCs), which may provide insights into the underlying pathogenesis of varicose vein.

{{ptg:RelatedPrimaryAntibodies}}